DUBLIN, Dec 19, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022" report to their offering.
At present the breast cancer vaccines are in emerging stages and this market has yet to be tapped by pharmaceutical companies. They are diverging funds towards research and development segment for advances in innovative breast cancer vaccines which will generate large amount of revenues. In recent years significant progress has been made on technological and scientific levels but still no vaccine for the treatment of breast cancer has seen market introduction in any part of the globe.
The present therapeutics available in market for breast cancer shows modest results in majority of patients which offers unexplored marketing opportunities for better innovative products to enter in competition. It is expected that more oncologists will prescribe the innovative breast cancer vaccines to their patients due to greater therapeutic effects. The higher rates of prescription would lead to high degree of market penetration and increased market share. The revenues generated in this way will encourage the pharmaceutical companies to fund new projects for the development of better breast cancer vaccines.
The first commercially available breast cancer vaccine is expected to be available in the market in next 5-7 years. Clinical trials would be able to come with thoroughly checked version of products under investigation which would be able to provide higher levels of medical care to breast cancer patients. Most of the innovative products are at the advance stages of clinical trials which are supposed to clear the targeted end points. Market introduction of these new products are supposed to generate significant revenues for the pharmaceutical companies in coming years.
Companies Mentioned:
- AVAX Technologies
- Advaxis
- AlphaVax
- Dendreon Corporation
- Galena Biopharma
- Generex Biotechnology
- GlaxoSmithKline
- Immune Design
- Immunovaccine
- Immunovative Therapies
- Imugene
- Inovio Pharmaceuticals
- Merck
- NewLink Genetics
- Recombio
- TapImmune
- ViroMed
Key Topics Covered:
1. What are Cancer Vaccines?
2. Mechanism of Cancer Vaccines
3. Mechanism of Breast Cancer Vaccine
4. Global Breast Cancer Incidence
5. Global Breast Cancer Vaccine Market Current Scenario
6. Need for Personalized Breast Cancer Vaccines
7. Global Breast Cancer Vaccine Market Dynamics
8. Global Breast Cancer Vaccine Market Future Prospects
9. FDA Guideline for the Development & Marketing of Cancer Vaccines
10. Global Breast Cancer Vaccine Clinical Pipeline by Company & Phase
11. Discontinued & Suspended Breast Cancer Vaccine in Clinical Pipeline by Company & Phase
12. Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/5cssx2/global_breast
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article